Back to search

Article

Potential Utility of PPARγ Agonists in the Eradication of Chronic Myeloid Leukemia Stem Cells

2025-08-06

Abstract excerpt

<title>Abstract</title> <p> Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML), yet persistent leukemia stem cells (LSCs) remain a barrier to cure. PPARγ agonists like pioglitazone have been proposed to enhance eradication of LSCs when used alongside TKIs. This study investigated the impact of adding pioglitazone to imatinib therapy in 26 newly diagnosed chronic-ph...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
edadc08d-6541-555c-9c83-f30fe3914ac6
DOI
10.21203/rs.3.rs-7140724/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Potential Utility of PPARγ Agonists in the Eradication of Chronic Myeloid Leukemia Stem CellsDOI 10.21203/rs.3.rs-7140724/v1
Select a neighboring publication to make it the new centre.